Defibrotide Sodium
Defibrotide Sodium is an antithrombotic and fibrinolytic agent derived from bovine pulmonary DNA. It is primarily used to treat severe hepatic veno-occlusive disease (sinusoidal obstruction syndrome) in patients undergoing hematopoietic stem cell transplantation. The medication works by restoring fibrinolytic balance and reducing endothelial cell damage in hepatic blood vessels.
Defibrotide Sodium is used to treat severe veno-occlusive disease of the liver following stem cell transplantation by promoting fibrinolysis and protecting the vascular endothelium.
Key facts at a glance
- RxNorm
- 1746523
- Generic
- Defibrotide Sodium
- Class
- pin-variant
- Brands
- Defitelio
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), in hematopoietic stem cell transplantation (HSCT) patients. It is specifically indicated for patients with renal or pulmonary dysfunction in addition to VOD.
Defibrotide Sodium exhibits antithrombotic, anti-ischemic, and anti-inflammatory properties. It increases tissue plasminogen activator (tPA) and thrombomodulin expression while decreasing plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor, restoring fibrinolytic balance and protecting the vascular endothelium from damage.
Major risk is hemorrhage, particularly in patients with compromised integrity of blood vessels. Contraindicated with concomitant systemic anticoagulant or thrombolytic therapy. Should be discontinued 2-4 hours prior to invasive procedures. Administered as a continuous IV infusion. Close monitoring for signs of bleeding is required throughout treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy